ArticleScientific reports2025
Comparison of inflammatory and nutritional markers obtained at the time of diagnosis in patients diagnosed with renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Prognostic Nutritional Index enhances risk stratification and predicts progression-free survival in upper tract urothelial carcinoma.Discover oncology · 2026Article
- Elevated preoperative inflammatory ratios (NLR/PLR) predict adverse pathology and poor surgical outcomes in metastatic renal cell carcinoma: a retrospective analysis.American journal of translational research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare the prognostic significance of inflammatory and nutritional parameters, calculated based on hemogram and biochemical values at the time of diagnosis, in patients diagnosed with renal cell carcinoma (RCC). A total of 120 patients diagnosed with RCC and receiving diagnosis and/or treatment at our center were included in the study. Among the inflammatory and nutritional parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS), and Memorial Sloan Kettering prognostic score (MPS) were calculated and analyzed. The most common pathological subtype was the clear cell variant (69.2%). 25.8% of the patients were at the metastatic stage. Univariate Cox regression analysis revealed that tumor size, tumor grade, sex, stage, presence of metastasis, number of metastases, IVC involvement, history of radiotherapy (RT), hemoglobin, NLR, PLR, PNI, albumin, C-reactive protein (CRP), MPS, and mGPS had a significant impact on survival. Furthermore, stage, number of metastases, and PNI were identified as independent prognostic factors for survival. When clinical parameters were excluded from the analysis, NLR, LDH, and mGPS emerged as independent prognostic factors for survival.As demonstrated by the results of the multivariate analysis, stage, number of metastases, and PNI were found to be more influential independent prognostic factors. This study suggests that nutritional parameters have greater prognostic value than inflammatory markers in RCC, and that a simple nutritional scoring system performed at the time of diagnosis may provide improved prognostic accuracy. Additionally, our findings indicate that the MPS, which was evaluated for the first time in RCC in this study, also has prognostic significance, and it may potentially become an independent prognostic marker in future studies with larger patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.